AU2002222125A1 - Prevention and treatment of tachyphylactic response - Google Patents

Prevention and treatment of tachyphylactic response

Info

Publication number
AU2002222125A1
AU2002222125A1 AU2002222125A AU2212502A AU2002222125A1 AU 2002222125 A1 AU2002222125 A1 AU 2002222125A1 AU 2002222125 A AU2002222125 A AU 2002222125A AU 2212502 A AU2212502 A AU 2212502A AU 2002222125 A1 AU2002222125 A1 AU 2002222125A1
Authority
AU
Australia
Prior art keywords
tachyphylactic
prevention
response
treatment
tachyphylactic response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002222125A
Inventor
Clair Adcocks
Claes Bavik
Michael Cork
Gordon Duff
Rachid Tazi-Ahnini
Simon Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Skincare Ltd
Original Assignee
Molecular Skincare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Skincare Ltd filed Critical Molecular Skincare Ltd
Publication of AU2002222125A1 publication Critical patent/AU2002222125A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002222125A 2000-12-04 2001-12-04 Prevention and treatment of tachyphylactic response Abandoned AU2002222125A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0029524.6 2000-12-04
GBGB0029524.6A GB0029524D0 (en) 2000-12-04 2000-12-04 Disease treatment
PCT/GB2001/005369 WO2002045704A2 (en) 2000-12-04 2001-12-04 Prevention and treatment of tachyphylactic response

Publications (1)

Publication Number Publication Date
AU2002222125A1 true AU2002222125A1 (en) 2002-06-18

Family

ID=9904393

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002222125A Abandoned AU2002222125A1 (en) 2000-12-04 2001-12-04 Prevention and treatment of tachyphylactic response

Country Status (3)

Country Link
AU (1) AU2002222125A1 (en)
GB (1) GB0029524D0 (en)
WO (1) WO2002045704A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128415D0 (en) * 2001-11-27 2002-01-16 Univ Sheffield Medicaments
GB0128628D0 (en) * 2001-11-29 2002-01-23 Univ Sheffield Disease treatment
AU2003200611C1 (en) * 2002-02-22 2005-08-04 Fci Holdings Delaware, Inc. Yieldable prop
WO2006032299A1 (en) * 2004-09-24 2006-03-30 Susanna Miettinen Use of inhibitors of 24-hydroxylase in the treatment of cancer
WO2008156661A2 (en) * 2007-06-15 2008-12-24 Beth Israel Deaconess Medical Center BACTERIAL MEDIATED TNF-α GENE SILENCING

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9409882D0 (en) * 1994-05-18 1994-07-06 Sandoz Ltd Organic compounds
US5658881A (en) * 1994-10-14 1997-08-19 Twk, Inc. Method for topical inhibition of the metabolic activity of cytochrome P450
US5998393A (en) * 1996-04-05 1999-12-07 Kang; Sewon Methods for assessing 1,25(OH)2 D3 activity in skin and for enhancing the therapeutic use of 1,25(OH)2 D3
GB9800040D0 (en) * 1998-01-02 1998-03-04 Univ Cardiff Pyrrolidine dione derivatives
US20010041706A1 (en) * 2000-03-24 2001-11-15 Synold Timothy W. Blockade of taxane metabolism

Also Published As

Publication number Publication date
WO2002045704A2 (en) 2002-06-13
WO2002045704A3 (en) 2003-05-01
GB0029524D0 (en) 2001-01-17

Similar Documents

Publication Publication Date Title
WO2001078781A8 (en) Methods for prevention and treatment of gastrointestinal disorders
AU2002323210A1 (en) Bio-synthetic photostimulators and methods of use
AU2001265008A1 (en) Caspase inhibitors and uses thereof
AU2001239052A1 (en) Compositions for prevention and treatment of dementia
AU2002314466A1 (en) Withasol and methods of use
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2001243219A1 (en) Methods of prevention and treatment of asthma, and allergic conditions
AU2001281140A1 (en) Anti-plasmodium compositions and methods of use
AU2002335085A1 (en) Angiopoietins and methods of use thereof
AU2002231206A1 (en) Treatment of depression
AUPQ622600A0 (en) Treatment and/or prevention of ocular pain
AU5908300A (en) Prevention and treatment of amyloid-associated disorders
AU2002211370A1 (en) Inhibition of tgf-beta and uses thereof
AU6887101A (en) Copolymers and methods of treating prion-related diseases
AU7601400A (en) Treatment and prevention of hepatic disorders
AU2002222125A1 (en) Prevention and treatment of tachyphylactic response
AU2001245414A1 (en) Treatment of allergies
AU2001264863A1 (en) Preparation of fagopyritols and uses therefor
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2001261496A1 (en) Luxo-sigma54 interactions and methods of use
AU2001284380A1 (en) Therapeutic and cosmetic uses of heparanases
AU2001281950A1 (en) Regulation of human thimet oligopeptidase-like enzyme
AU3735900A (en) Methods of treatment and prevention of restenosis
AU1392601A (en) Prevention and treatment of biomaterial-associated infections
AU2001253560A1 (en) Methods of treatment